Mydecine is a biotechnology and digital technology company developing innovative second and third-generation novel therapeutics for the treatment of mental health and addiction through world-class technology and drug development infrastructure.
This is Our ProcessMydecine's mission is to become a trusted source of safe and effective medication‑based treatments to address the unmet needs for mental health and addiction disorders.
Through technology and research, our vision is to become the number one globally trusted leader in the treatment of mental health and addiction disorders. We see success when all medical and therapy communities view psychedelic medicine as an accepted and adopted form of treatment offered in our existing healthcare infrastructure.
The global economic costs of smoking (health expenditures and productivity losses together) 1
The expected reach of the global smoking cessation market 2
People are addicted to alcohol consumption, globally 3
Deaths per year due to smoking-related causes, globally 1
People will be diagnosed with PTSD in their lifetime, globally 4
Of veterans will develop PTSD 5
The frequency at which a U.S. veteran commits suicide 5
The global average of frontline workers developing PTSD 6
People suffer from some form of anxiety, globally 7
1World Health Organization
2ResearchandMarkets.com (2019)
3Institute for Health Metrics and Evaluation (2017)
4American Psychiatric Association (2013)
5U.S. Department of Veterans Affairs
6Occupational Health and Safety (2020)
7Institute for Health Metrics and Evaluation (2016)
The leadership and stakeholders of Mydecine draw from a variety of environments including academic, research and development, military, and corporate environments to lead our company in search of safer more effective treatments for mental health and addiction.